The predecessor of Kyoto Pharmaceutical Industries is Kyoto Seiyaku GSK (GoShi Kaisha or Limited Partnership Company) established in 1901. It was a company to manufacture and market industrial chemicals such as mordanting agent used for black dyeing and soap. However, due to outbreak of wars importation of oils and fats became difficult. Then in 1946 Kyoto Pharmaceutical Industries was founded as a drug manufacturer.

Please glance through the history of Kyoto Pharmaceutical Industries which has made incessant efforts to make contributions and return the gratitude to the society through discovery of novel candidate compounds and creation of original formulations for innovative drugs.

Corporate History

Years of Predawn

1901 Tokujiro Tanaka founded Kyoto Seiyaku GSK at Fukakusa, Fushimi-ku, Kyoto.
1917 Kyoto Seiyaku GSK was renamed to GSK Tanaka Chemical Industries.
Moved to the present location. Tokken Tanaka became Representative.

Years of Foundation

1946 Kyoto Pharmaceutical Industries, Ltd. was established with a capital of 150,000 yen.
Seijiro Kitao became Representative Director.
Manufacturing and marketing of Dartenon Tablets (antidiarrheal).
1947 Manufacturing and marketing of Hustosil Syrup (antitussive and expectorant)
1948 Started transactions with Inabata & Co., Ltd.
1949 Launched Hustosil Injection (antitussive and expectorant)
1951 Started transactions with Nishinippon Pharmaceutical Co., Ltd. (now Nippo Pharmaceutical Co., Ltd.).
1954 Launched Dartenon Tablets (antidiarrheal) through Nishinippon Pharmaceutical Co., Ltd.

Years of Growth

1958 Increased capital to 6 million yen.
1959 Launched Myoseden Tablets (muscle relaxant analgesic) through Inabata & Co., Ltd.
1960 Completed Chemical Research Laboratory.
1963 Completed Formulation Plant (now Biological Research Laboratory).
1965 Increased capital to 30 million yen.
1967 Completed the Head Office building.
1968 Joined the Japan Pharmaceutical Manufacturers Association. Launched Vastarel F Tablets (treatment of ischemic heart disease) through Inabata & Co., Ltd.
1969 Increased capital to 75 million yen.
1970 Completed No.1 Formulation Plant and Biological Research Laboratory.
1972 Dissolution of Tanaka Chemical Industries.

Years of Transition

1975 Increased capital to 150 million yen.
Completed the extension of the formulation plant which meets GMP standards.
1978 Opened Tokyo Branch Office.
1980 Implemented Japan’s first automated unmanned nighttime tableting.
1981 Increased capital to 180 million yen.
1984 Completed No.1 Formulation Facility (Suppository Facility) at Osadano Plant
1985 Launched Natrix Tablets (antihypertension) through Sumitomo Pharmaceuticals Co., Ltd. (now Sumitomo Pharma Co., Ltd.).

Years of Challenge

1987 Kazuhiko Kitao became President and CEO.
1990 Launched Vonfenac Suppository (analgesic and anti-inflammatory) through Zeria Pharmaceutical Co., Ltd.
1993 Launched New Lecicarbon Suppository (treatment of constipation) through Zeria Pharmaceutical Co., Ltd.
1995 Introduced Corporate Identity and established a new corporate emblem.
1996 Celebrated the 50th anniversary of the founding.
Published “The 50 Years of Kyoto Pharmaceutical Industries.”

Years of Quantum Leap

1998 Established Kyoto Healthcare Co., Ltd. (now Kyotoyakuhin Healthcare Co., Ltd.). Launched Emeradole Capsules through Kyowa Kogyo Co., Ltd. (now Kyowa Kirin Co., Ltd.).
2001 Launched New APPETATE Seichoyaku (regulation of intestinal function)
2002 Launched Raibell White (vitamin C supplement compounded with L-Cysteine) through Yamanouchi Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.). Launched Digoxin-KY Tablets 0.25 and Halfdigoxin-KY Tablets 0.125 (digitalis preparations) through TOA EIYO LTD.
2003 Launched Colac Suppository Type through Taisho Pharmaceutical Co., Ltd.
2004 Completed No.2 Formulation Facility (Solid Formulation Facility) at Osadano Plant.
2005 Took over the business for health foods from Marupi Pharmaceutical Co., Ltd. ,a subsidiary of Pharmaceutical Co., Ltd. (now Sumitomo Pharma Co., Ltd.).
2006 Completed Formulation Research Laboratory.
Celebrated the 60th anniversary of the founding.
Published “The History of Seijiro Kitao, Founder of Kyoto Pharmaceutical Industries.”
2010 Completed No.3 Formulation Facility (Solid Formulation Facility) at Osadano Plant.
2011 Completed an automated warehouse at Osadano Plant.


Launched TRANSINO White-C through Daiichi Sankyo Healthcare Co., Ltd.The 30th anniversary of the completion of No.1 Formulation Facility at Osadano Plant.
Celebrated the 10th anniversary of No.2 Formulation Facility.
2015 Launched Digoxin Tablets 0.0625 KYO (digitalis preparation) through TOA EIYO LTD.
2016 Celebrated the 70th anniversary of the founding.
Published "The 70 Years of Kyoto Pharmaceutical Industries."
2017 Decreased capital to 90 million yen.
2021 Completed the No.2 Formulation Plant.
2022 Kazuhiko Kitao becomes Representative Director, Chairman and CEO.
Seishi Kitao becomes Representative Director, President and CEO.
page top